EGFR and non-small cell lung carcinoma: Gefitinib and erlotinib are so-called first-generation EGFR–TKIs that were proven to be efficacious for NSCLC harbouring an EGFR mutation (EGFR-activating mutation; exon 19 deletion [del19] or L858R point mutation in exon 21 [L858R]).